Venous Thromboembolism – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 7 PAGES: 94

More Info
									Venous Thromboembolism – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1818IDB
                                                                                           Publication Date: February 2012




Venous Thromboembolism – Pipeline Review, H1 2012                                          GMDHC1818IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Venous Thromboembolism – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 6
    List of Figures ................................................................................................................................................................................ 7
Introduction......................................................................................................................................................................................... 8
    Global Markets Direct Report Coverage ........................................................................................................................................ 8
Venous Thromboembolism Overview ................................................................................................................................................. 9
Therapeutics Development............................................................................................................................................................... 10
    An Overview of Pipeline Products for Venous Thromboembolism............................................................................................... 10
Venous Thromboembolism Therapeutics under Development by Companies ................................................................................. 12
Venous Thromboembolism Therapeutics under Investigation by Universities/Institutes .................................................................. 14
Late Stage Products ......................................................................................................................................................................... 16
    Comparative Analysis .................................................................................................................................................................. 16
Mid Clinical Stage Products.............................................................................................................................................................. 17
    Comparative Analysis .................................................................................................................................................................. 17
Early Clinical Stage Products ........................................................................................................................................................... 18
    Comparative Analysis .................................................................................................................................................................. 18
Pre-Clinical Stage Products.............................................................................................................................................................. 19
    Comparative Analysis .................................................................................................................................................................. 19
Venous Thromboembolism Therapeutics – Products under Development by Companies ............................................................... 20
Venous Thromboembolism Therapeutics – Products under Investigation by Universities/Institutes ................................................ 21
Companies Involved in Venous Thromboembolism Therapeutics Development .............................................................................. 22
    Bristol-Myers Squibb Company ................................................................................................................................................... 22
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 23
    Sanofi-Aventis ............................................................................................................................................................................. 24
    Daiichi Sankyo Company, Ltd...................................................................................................................................................... 25
    Novartis AG ................................................................................................................................................................................. 26
    Bayer AG ..................................................................................................................................................................................... 27
    ARYx Therapeutics...................................................................................................................................................................... 28
    Portola Pharmaceuticals, Inc. ...................................................................................................................................................... 29
    Emisphere Technologies, Inc. ..................................................................................................................................................... 30
    Cristalia Produtos Quimicos Farmaceuticos Ltda. ....................................................................................................................... 31
    Endotis Pharma ........................................................................................................................................................................... 32
    Regado Biosciences. ................................................................................................................................................................... 33
Venous Thromboembolism – Therapeutics Assessment ................................................................................................................. 34
    Assessment by Monotherapy Products ....................................................................................................................................... 34
    Assessment by Route of Administration ...................................................................................................................................... 35
    Assessment by Molecule Type .................................................................................................................................................... 37
Drug Profiles..................................................................................................................................................................................... 39
    Edoxaban - Drug Profile .............................................................................................................................................................. 39
         Product Description................................................................................................................................................................. 39
         Mechanism of Action ............................................................................................................................................................... 39
         R&D Progress ......................................................................................................................................................................... 39



Venous Thromboembolism – Pipeline Review, H1 2012                                                                                           GMDHC1818IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Venous Thromboembolism – Pipeline Review, H1 2012




    Eliquis - Drug Profile .................................................................................................................................................................... 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    Betrixaban - Drug Profile ............................................................................................................................................................. 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    AVE5026 - Drug Profile ............................................................................................................................................................... 45
        Product Description................................................................................................................................................................. 45
        Mechanism of Action ............................................................................................................................................................... 45
        R&D Progress ......................................................................................................................................................................... 45
    AVE5026 - Drug Profile ............................................................................................................................................................... 46
        Product Description................................................................................................................................................................. 46
        Mechanism of Action ............................................................................................................................................................... 46
        R&D Progress ......................................................................................................................................................................... 46
    Xarelto - Drug Profile ................................................................................................................................................................... 47
        Product Description................................................................................................................................................................. 47
        Mechanism of Action ............................................................................................................................................................... 47
        R&D Progress ......................................................................................................................................................................... 47
    ATI-5923 - Drug Profile ................................................................................................................................................................ 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    Pradaxa - Drug Profile ................................................................................................................................................................. 50
        Product Description................................................................................................................................................................. 50
        Mechanism of Action ............................................................................................................................................................... 50
        R&D Progress ......................................................................................................................................................................... 50
    EP37151 - Drug Profile ................................................................................................................................................................ 51
        Product Description................................................................................................................................................................. 51
        Mechanism of Action ............................................................................................................................................................... 51
        R&D Progress ......................................................................................................................................................................... 51
    Oral Heparin - Drug Profile .......................................................................................................................................................... 52
        Product Description................................................................................................................................................................. 52
        Mechanism of Action ............................................................................................................................................................... 52
        R&D Progress ......................................................................................................................................................................... 52
    REG2 - Drug Profile..................................................................................................................................................................... 53
        Product Description................................................................................................................................................................. 53
        Mechanism of Action ............................................................................................................................................................... 53
        R&D Progress ......................................................................................................................................................................... 53
    Certoparin - Drug Profile .............................................................................................................................................................. 55
        Product Description................................................................................................................................................................. 55
        Mechanism of Action ............................................................................................................................................................... 55
        R&D Progress ......................................................................................................................................................................... 55


Venous Thromboembolism – Pipeline Review, H1 2012                                                                                       GMDHC1818IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                               Page(3)
Venous Thromboembolism – Pipeline Review, H1 2012




    Dalteparin Sodium - Drug Profile ................................................................................................................................................. 56
        Product Description................................................................................................................................................................. 56
        Mechanism of Action ............................................................................................................................................................... 56
        R&D Progress ......................................................................................................................................................................... 56
    Aspirin - Drug Profile ................................................................................................................................................................... 57
        Product Description................................................................................................................................................................. 57
        Mechanism of Action ............................................................................................................................................................... 57
        R&D Progress ......................................................................................................................................................................... 57
    Aspirin - Drug Profile ................................................................................................................................................................... 58
        Product Description................................................................................................................................................................. 58
        Mechanism of Action ............................................................................................................................................................... 58
        R&D Progress ......................................................................................................................................................................... 58
    Actiparin - Drug Profile ................................................................................................................................................................ 59
        Product Description................................................................................................................................................................. 59
        Mechanism of Action ............................................................................................................................................................... 59
        R&D Progress ......................................................................................................................................................................... 59
    Sodium Heparin - Drug Profile ..................................................................................................................................................... 60
        Product Description................................................................................................................................................................. 60
        Mechanism of Action ............................................................................................................................................................... 60
        R&D Progress ......................................................................................................................................................................... 60
    Heptar - Drug Profile.................................................................................................................................................................... 62
        Product Description................................................................................................................................................................. 62
        Mechanism of Action ............................................................................................................................................................... 62
        R&D Progress ......................................................................................................................................................................... 62
    Alimax - Drug Profile.................................................................................................................................................................... 64
        Product Description................................................................................................................................................................. 64
        Mechanism of Action ............................................................................................................................................................... 64
        R&D Progress ......................................................................................................................................................................... 64
    Dalteparin Sodium - Drug Profile ................................................................................................................................................. 66
        Produc
								
To top